You can now review and comment on this draft guideline.
The consultation closes on 27 April 2022 at 5pm
How to comment
1. Register your organisation or comment as an individual
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.
Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.
We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.
2. Read the consultation documents
Documents to comment on:
- Draft guideline – just the recommendations
- Evidence review - Periodontal treatment to improve diabetic control in adults with type 1 or type 2 diabetes
Other information about the consultation
- Equality impact assessment 3
- Committee membership list
- Developing NICE guidelines: how to get involved
3. Add your comments
- You must use this comments form.
- You must declare any links with, or funding from, the tobacco industry
If you share similar views with another organisation, send a joint response.
Make sure you consider:
- The areas that will have the biggest impact on practice and be challenging to implement
- How to help users overcome challenges
Developing NICE guidelines: how to get involved suggests some other areas to comment on.
4. Email the form to us
Email: t1diabetesadults@nice.org.uk
Deadline: 27 April 2022 at 5pm
We are consulting separately on updates to our guidelines on Type 1 diabetes in adults, Type 2 diabetes in adults, and Diabetes (type 1 and type 2) in children and young people. There is a separate comment form for each topic. Please ensure your comments are added to the relevant form and submitted to the correct email address, as stated on each form. Please note, the evidence review for the adults population underpins both the Type 1 and Type 2 guidelines. If you will be commenting on the consultations for both the Type 1 and Type 2 populations and wish to make comments regarding the evidence review document, you only need to submit those comments on one form – you don’t need to repeat your comments across both forms. Please continue to submit your comments on the guideline document itself on the separate forms.
This page was last updated: